Company intelligence / Profile preview
Aston
Seoul, Seoul, South Koreaastonsci.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Aston Sci. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies—primarily therapeutic and prophylactic vaccines—for oncology, immunology, and geriatrics. The company’s lead programs include AST-201 for ovarian cancer and AST-301 for HER2-expressing cancers. Both have entered Phase 2 trials with regulatory approvals in the US and Taiwan respectively. The Th-Vac® platform underpins their approach to rapid epitope discovery for next-generation vaccines.
- Therapeutic areas
- Oncology
- Modalities
- VaccineTherapeutic cancer vaccineProphylactic vaccineImmunotherapy (platform-based)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
NH Investment & Securities selected as listing manager for IPO process; no major pharma partnerships publicly disclosed as of June 2025
Beyond the preview
Go deeper on Aston.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aston.